# Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

> **NCT05036798** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05036798
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-17
- **Primary completion:** 2022-07-02
- **Final completion:** 2023-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036798, "Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05036798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*